Solidification of SNEDDS Using Mesoporous Carriers (2020-2025): A Review of Design, Biopharmaceutical Enhancement,...

Self-nanoemulsifying drug delivery systems (SNEDDS) have been widely developed as a practical approach to enhance the bioavailability of poorly water-soluble drugs through nanoscale emulsification. To improve the stability and practicality of liquid systems, solidification is commonly performed to obtain solid SNEDDS (S-SNEDDS) by incorporating appropriate solid carriers. Among various options, mesoporous materials have attracted significant attention due to their high surface area, tunable pore sizes, and excellent adsorption capacity. This review aims to summarize and critically analyze recent advances in mesoporous-based S-SNEDDS, focusing on formulation design, solidification strategies, and associated biopharmaceutical outcomes. The review is based on research articles published between 2020 and 2025 retrieved from reputable scientific databases (PubMed, ScienceDirect, Taylor & Francis, Springer, Scopus, and Web of Science) and selected for their relevance to mesoporous carriers and S-SNEDDS development. Findings reveal that carriers such as mesoporous magnesium alumino-metasilicate (eg, Neusilin^®) and mesoporous silica (eg, Syloid^®) have primarily been reported in studies employing physical adsorption. These systems generally exhibit favorable micromeritic properties and solid-state characteristics, suggesting successful drug incorporation within the carrier matrix and improved physical stability. These systems consistently demonstrate enhanced dissolution and permeation, and subsequently translate into superior pharmacokinetic and pharmacodynamic performances. Overall, the solidification of SNEDDS using mesoporous carriers successfully yields systems with desirable physical properties and improved in vitro and in vivo performances. Future research should address regulatory considerations for mesoporous excipients, deepen mechanistic insights into drug-carrier interactions, and include comparative evaluations among different carriers to support clinical and industrial advancement.